Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T08:54:59.125Z Has data issue: false hasContentIssue false

Medication adherence in schizophrenia

Published online by Cambridge University Press:  23 March 2020

F. Fatma
Affiliation:
Hédi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
I. Baati
Affiliation:
Hédi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
S. Omri
Affiliation:
Hédi Chaker University Hospital, Psychiatry A, Sfax, Tunisia
J. Masmoudi
Affiliation:
Hédi Chaker University Hospital, Psychiatry A, Sfax, Tunisia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Compliance is a major issue in the treatment of schizophrenia. Many studies have attempted to identify factors that influence it.

Objective

To assess treatment adherence in patients with schizophrenia. To identify factors correlated with poor adherence.

Methods

It was a cross-sectional, descriptive and analytical study, involving 37 outpatients with DSM-IV diagnosis of schizophrenia, followed in the psychiatry department at the Hédi Chaker University Hospital of Sfax (Tunisia). The questionnaire included socio-demographic, clinical and therapeutic data. We also used the Medication Adherence Rating Scale “MARS”, the Insight Scale “IS” and the Stigma Scale (9 items).

Results

The average age was 36.4 years. The majority of patients was male (68.8%), did not exceed the level of secondary education (89.2%) and had a low socioeconomic level (84.4%).

Paranoid schizophrenia was the most frequent type of schizophrenia (54.1%). Atypical antipsychotic were prescribed in 40.5% of cases.

Patients were non-adherent to treatment in 56.8% of cases. The factors correlated with poor adherence were: psychoactive substance use (P = 0.036), sexual dysfunction (P = 0.036), complexity of treatment (P = 0.036), poor insight according to the subscale “awareness of the need for treatment” of the IS (P = 0.047) and high score on the subscale “discrimination” of the Stigma Scale (P = 0.008).

Conclusion

Tunisian schizophrenic patients have a poor adherence to treatment. Acting on risk factors (such as substance use, sexual side effects, poor insight and discrimination perception) would improve patient compliance and management of schizophrenia.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV1193
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.